Enanta Pharmaceuticals | ENTA - Gross Profit On Sales


Enanta Pharmaceuticals reported -22.29M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Immunic 0 0 Mar/2025
Incyte USD 1.17B 217.51M Mar/2026
Insmed USD 256.46M 38.78M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
J&J USD 17.24B 642M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026